Valentis

Valentis is a biotechnology company that was engaged in the development of innovative products for peripheral arterial disease (PAD), a large and unsatisfied market. On July 11, 2006 Valentis announced that no statistically significant difference was seen in the primary endpoint or any of the secondary endpoints in its Phase IIb clinical trial of VLTS 934 in PAD. The primary efficacy endpoint in the study was improvement in exercise tolerance on an escalating grade treadmill after 90 days in patients receiving VLTS 934 versus patients receiving placebo. While Valentis focused its efforts on the development of novel peripheral arterial disease therapeutics, its technologies are being applied by its collaborators for the development of therapeutics to treat a variety of indications including infectious diseases and cancer.

Contact Details: 533 Airport Blvd Ste. 400 Burlingame CA 94010 United States of America Tel: 650 697 1900 Fax: 650-652-1990 Email: ir@valentis.com WWW: www.valentis.com/

Loading...

Recent Publications by Valentis:
The antiprogestin-dependent GeneSwitch system for regulated gene therapy. Antiprogestin-controlled gene regulation systems, initially developed by...	18th August, 2004	Valentis, Inc., 863A Mitten Road, Burlingame, CA 94010, USA.	Steroids. 2003 Nov;68(10-13):1085-94.
Regulated production of proteins from muscle using gene transfer: potential therapeutic applications. The ability to produce high-level transgene expression following the...	14th July, 2004	Valentis, Inc, Burlingame, CA 94010, USA.	Expert Opin Biol Ther. 2003 Apr;3(2):277-91. DOI Direct Link
Biodistribution and safety studies of hDel-1 plasmid-based gene therapy in mouse and rabbit models. A plasmid encoding the human developmentally regulated endothelial locus-1...	24th June, 2004	Valentis,	J Pharm Pharmacol. 2004 Feb;56(2):177-85. DOI Direct Link
Plasmid-based gene transfer and antiprogestin-controllable transgene expression. Inhibition of the neovascularization of tumors has proven efficacious in...	30th January, 2004	Valentis, Inc., 8301 New Trails Drive, The Woodlands, TX 77381, USA.	Ernst Schering Res Found Workshop. 2003;(43):225-44.
Antiprogestin-controllable transgene regulation in vivo. Gene control systems that provide temporal and spatial regulation of...	13th March, 2003	Valentis,	Curr Opin Biotechnol. 2002 Oct;13(5):453-8.
→View more Valentis research publications.

Press Releases on Valentis:
Vical Executive Alain Rolland Named AAPS Fellow	17th November, 2008	Vical Incorporated	ATLANTA, Nov. 17 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that Alain P. Rolland, Pharm.D., Ph.D., the company's Senior Vice President, Product Development, was
Oxford Biomedica plc awarded $0.5 million grant for motor neuron disease	1st December, 2002	Oxford Biomedica	Oxford Biomedica plc awarded $0.5 million grant for motor neuron disease programme Oxford, UK 17 December 2002 - Oxford
Oxford Biomedica plc update on cancer clinical plans	1st November, 2002	Oxford Biomedica	Oxford Biomedica plc update on cancer clinical plans Oxford, United Kingdom – 8 November 2002. Oxford BioMedica plc (LSE:OXB) is
Oxford Biomedica plc David Higgins appointed vice president for business	1st November, 2002	Oxford Biomedica	Oxford Biomedica plc David Higgins appointed vice president for business development     14th November 2002 Oxford,
ARIUS Research Inc. and Oxford BioMedica plc: collaboration attracts	1st October, 2002	Oxford Biomedica	ARIUS Research Inc. and Oxford BioMedica plc: collaboration attracts first development partner in Protein Design Labs Inc. Oxford,

Valentis Clinical Trials:
Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease

Valentis Patents:
US Patent No.	Title
7314746	Apparatus and method for preparative scale purification of nucleic acids
6235310	Methods of delivery using cationic lipids and helper lipids
6271206	Sonic nebulized nucleic acid/cationic liposome complexes and methods for pulmonary gene delivery
6271209	Cationic lipid formulation delivering nucleic acid to peritoneal tumors
6303378	Methods for preparing polynucleotide transfection complexes
→View more Valentis patents.

Valentis (VLTS) Financial information Links from Barchart
VLTS Quote from from Barchart.com
VLTS Chart from from Barchart.com
VLTS Profile from from Barchart.com
VLTS Opinion from from Barchart.com
→View more Valentis finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 742 times since April 2007, the link to the organisation's website has been followed 172 times

Recent Search Terms used to find this page: Valentis Burlingame | valentis gene therapy | VALENTIS INC burlingame | valentis burlingame pharmaceutical | .

Search for more companies in Burlingame

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Valentis